renal cancer
MD Anderson, Summit Therapeutics to Jointly Study Ivonescimab
The partners inked a five-year deal to study the PD-1/VEGF bispecific antibody across multiple tumor types, including in biomarker-defined indications.
Investigators last month published early results, which they believe have set a solid foundation for the independent value of their novel signature.
Merck, Moderna Personalized Neoantigen Vaccine, Keytruda Combo Still Benefiting Melanoma Patients
Premium
After three years of follow-up, mRNA-4157 plus Keytruda led to a 49 percent reduction in the risk of disease recurrence or death versus Keytruda alone.
The firm is evaluating if an oral pill containing the bacteria Akkermansia can improve immunotherapy responses among lung and kidney cancer patients.
Calithera Biosciences Focuses Telaglenastat Development in Lung Cancer After Renal Cancer Study Failure
After the CANTATA trial failed, the company said it will reduce its workforce and direct resources to advancing the drug in KEAP1/NRF2-mutated NSCLC.